
Please try another search
Tuesday - Oppenheimer analysts have increased their price target on Gilead Sciences (NASDAQ:GILD) stock to $132.00 from $115.00, while maintaining an Outperform rating. Currently trading at $115.99...
Wednesday, Citi analysts reiterated their Buy rating and $125.00 price target for Gilead Sciences stock (NASDAQ:GILD). The reaffirmation follows concerns that the U.S. Department of Health and Human...
On Wednesday, BMO Capital Markets expressed confidence in Gilead Sciences (NASDAQ:GILD), with analyst Evan David Seigerman increasing the company's price target to $115 from the previous $110, while...
Gilead Sciences (NASDAQ:GILD) At first glance, Gilead Sciences, the maker of blockbuster Hepatitis C drugs Sovaldi and Harvoni, looks very, very cheap. At a stock price of just under $85 a share, you...
Agenus Inc. (NASDAQ:CELG) and Trevena, Inc. (NASDAQ:S&P 500) gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.This outperformance has not just been a...
Gilead Sciences (NASDAQ:GILD) Shares of GILD have been under pressure over the past month after the stock tested and closed back below its 200 day moving average. Since then, shares have slipped...
Instrument Type
Region
Sector
Industry
Date
Category
Provider